ArticleEuropean journal of nutrition2026
Chlorogenic acid alleviates endothelial cell inflammation and apoptosis of Kawasaki disease.
Article in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeKawasaki disease (KD) is an acute, self-limiting artery vasculitis, especially involving the coronary arteries. Chlorogenic acid (CGA) is a plant-derived polyphenolic compound with anti-inflammatory, anti-apoptotic, and anti-oxidative pharmacological effects. The purpose of this study was to explore the protective effects of CGA on KD and elucidate its mechanisms.
methodsCandida albicans water-soluble fraction (CAWS) was used to establish a KD mouse model with coronary arteritis, and tumor necrosis factor α (TNF-α) was employed to induce human umbilical vein endothelial cell (HUVEC) injury of KD cell model, which was administrated in different ways and analyzed by hematoxylin–eosin (HE) staining, Masson trichrome staining, TdT-mediated dUTP Nick-End Labeling (TUNEL) staining, immunofluorescence staining, western blotting immunohistochemistry staining, real-time quantitative polymerase chain reaction (RT-qPCR), and so on.
resultsIn vivo results showed that CGA could exert protective effects on KD mice through alleviating inflammation and fibrosis around the coronary arteries, and relieving vascular endothelial cell apoptosis. In vitro studies confirmed that CGA could inhibit TNF-α induced inflammation of HUVECs, similar to the NF-κB inhibitor QNZ. Additionally, it can also inhibit TNF-α induced HUVEC apoptosis by increasing BCL-2 expression as well as reducing TUNEL positive cells, the rates of flow cytometric apoptotic cells, and BAX expression. These effects could be reversed by the AMPK inhibitor compound c (CC). Further mechanistic study based on bioinformatics analysis and western blotting revealed that CGA could protect against vascular inflammation and cell apoptosis of KD through regulating the AMPK/mTOR/NF-κB pathway.
conclusionCGA may have the potentially protective effects on KD through inhibition endothelial cell inflammation and apoptosis, suggesting that CGA may serve as an adjuvant for KD therapy in the future.
Indexed as
Identifiers
41984219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.